Viridian Therapeutics Inc (NASDAQ: VRDN) is -8.36% lower on its value in year-to-date trading and has touched a low of $11.40 and a high of $27.20 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VRDN stock was last observed hovering at around $20.09 in the last trading session, with the day’s loss setting it -0.13%.
Currently trading at $19.96, the stock is -8.06% and -11.92% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.27 million and changing -0.65% at the moment leaves the stock 15.48% off its SMA200. VRDN registered 11.63% gain for a year compared to 6-month gain of 61.75%. The firm has a 50-day simple moving average (SMA 50) of $22.685 and a 200-day simple moving average (SMA200) of $17.280775.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -12.61% loss in the last 1 month and extending the period to 3 months gives it a 48.18%, and is -8.90% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.82% over the week and 5.87% over the month.
Viridian Therapeutics Inc (VRDN) has around 96 employees, a market worth around $1.58B and $0.30M in sales. Profit margin for the company is -85127.15%. Distance from 52-week low is 75.09% and -26.62% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.21%).
The EPS is expected to grow by 24.09% this year
237.0 institutions hold shares in Viridian Therapeutics Inc (VRDN), with institutional investors hold 112.08% of the company’s shares. The shares outstanding are 79.18M, and float is at 70.14M with Short Float at 12.97%. Institutions hold 112.08% of the Float.
The top institutional shareholder in the company is FMR LLC with over 9.57 million shares valued at $124.55 million. The investor’s holdings represent 15.6686 of the VRDN Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 4.77 million shares valued at $62.1 million to account for 7.8129 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 3.92 million shares representing 6.4221 and valued at over $51.05 million, while VR ADVISER, LLC holds 6.3547 of the shares totaling 3.88 million with a market value of $50.51 million.
Viridian Therapeutics Inc (VRDN) Insider Activity
The most recent transaction is an insider purchase by Beetham Thomas W., the company’s Chief Operating Officer. SEC filings show that Beetham Thomas W. bought 5,000 shares of the company’s common stock on Sep 27 ’24 at a price of $23.41 per share for a total of $0.12 million. Following the purchase, the insider now owns 6000.0 shares.
Viridian Therapeutics Inc disclosed in a document filed with the SEC on Sep 27 ’24 that Mahoney Stephen F. (President and CEO) bought a total of 21,400 shares of the company’s common stock. The trade occurred on Sep 27 ’24 and was made at $23.33 per share for $0.5 million. Following the transaction, the insider now directly holds 21400.0 shares of the VRDN stock.
Still, SEC filings show that on Sep 13 ’24, Fairmount Funds Management LLC (Director) acquired 1,600,000 shares at an average price of $18.75 for $30.0 million. The insider now directly holds 3,445,813 shares of Viridian Therapeutics Inc (VRDN).
